<DOC>
	<DOCNO>NCT02071082</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) fixed-dose combination ( FDC ) human immunodeficiency virus ( HIV ) /hepatitis B virus ( HBV ) coinfected adult . Participants enrol two cohort : - Cohort 1 : HIV/HBV coinfected adult HIV treatment-naive HBV treatment-naive - Cohort 2 : HIV/HBV coinfected adult HIV-suppressed</brief_summary>
	<brief_title>Efficacy Safety E/C/F/TAF ( Genvoya® ) HIV-1/Hepatitis B Co-infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Key Both Cohorts 1 2 : The ability understand sign write informed consent form , must obtain prior initiation study procedure HIV/HBV coinfected adult male nonpregnant nonlactating female No evidence hepatocellular carcinoma ( HCC ) clinical image evidence cirrhosis ( ascites , variceal bleeding , encephalopathy ) . Subjects documentation abdominal ultrasound 12 month prior screen , abdominal ultrasound screening , demonstrate absence cirrhosis HCC . Acute Hepatitis A virus ( HAV ) immunoglobulin M ( IgM ) negative Hepatitis C virus ( HCV ) Ab negative , HCV Ab positive negative HCV RNA Hepatitis D virus ( HDV ) Ab negative , HDV Ab positive negative HDV RNA Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min accord CockcroftGault formula CD4+ count &gt; 200 cells/μL Chronic HBV infection define HBsAg positive ≥ 6 month Or HBsAg positive screening either hepatitis B e antigen ( HBeAg ) HBV DNA positive ≥ 6 month Or At screening : positive total hepatitis B core antibody ( HBcAb ) negative immunoglobulin M antibody hepatitis B core antigen ( HBcIgM ) antibody , HBsAg positive , HBeAg positive , HBV DNA positive Cohort 1 ( HIV HBV treatment naive ) : No current prior antiHIV treatment , include antiretroviral medication receive prevention ( PrEP ) , post exposure prophylaxis ( PEP ) No current prior antiHBV treatment Plasma HIV1 RNA level ≥ 500 copies/mL screen Screening HBV DNA ≥ 3 log10 IU/mL &lt; 9 log10 IU/mL Cohort 2 ( HIV suppress ) : Receiving current antiretroviral regimen least 4 consecutive month No current prior regimen contain 3 active antiHBV agent ( i.e . tenofovir alafenamide ( TDF ) /emtricitabine ( FTC ) /Entecavir TDF/lamivudine ( 3TC ) /Entecavir ) Maintained plasma HIV1 RNA &lt; 50 copies/mL 6 consecutive month prior time screen visit . Unconfirmed virologic evaluation ≥ 50 copies/mL previously reach viral suppression ( transient detectable viremia , `` blip '' ) prior screen acceptable Documented positive HIV antibody test Screening HBV DNA &lt; 9 log10 IU/mL Key Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Have implant defibrillator pacemaker Current alcohol substance use A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive carcinoma . Received solid organ bone marrow transplant Any history , current evidence , clinical hepatic decompensation ( e.g. , ascites , encephalopathy variceal hemorrhage ) . Significant bone disease ( e.g. , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochondroses ) , multiple bone fracture Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 Subjects hemodialysis , form renal replacement therapy , treatment underlie kidney disease ( include prednisolone , dexamethasone ) Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement Investigational agent ( unless approve Gilead Sciences ) . Participation clinical trial without prior approval sponsor prohibit participate trial Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HBV</keyword>
	<keyword>Coinfection</keyword>
</DOC>